

The Role of Tumor Necrosis Factor-alpha (TNF- α) in the Pathogenesis of Oral Diseases

Marjan Sharifi¹, Mahsa Sharifi¹, Rania Younis^{2,3} and Meenakshi A Chellaiah^{1*}

¹Department of Oncology and Diagnostic Sciences, School of Dentistry, University of Maryland, Baltimore, United States

²Oral pathology division, Department of Oncology and Diagnostic Sciences, School of Dentistry, University of Maryland, Baltimore, United States

³Division of Tumor Immunology and Immunotherapy, Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, United States

*Corresponding author: Meenakshi Chellaiah, Ph.D., Department of Oncology and Diagnostic Sciences, School of Dentistry, University of Maryland, Baltimore, MD 21201, United States, Tel: 4107062083, E-mail: mchellaiah@umaryland.edu

Received Date: December 11, 2021 Accepted Date: January 08, 2022 Published Date: January 25, 2022

Citation: Marjan Sharifi (2022) The Role of Tumor Necrosis Factor-alpha (TNF- α) in the Pathogenesis of Oral Diseases. J Dent Oral Health 9: 1-14.

Abstract

Tumor necrosis factor-alpha (TNF- α) is a proinflammatory cytokine produced by various types of cells in the body. These cells are essential for the normal function of the immune system and play a critical role during infection and inflammation. TNF- α plays a crucial role in regulating various physiological functions of cells. Also, this cytokine mediates immune and inflammatory responses. Many cytokines expressed due to inflammatory diseases impact bone loss by increasing osteoclast differentiation and activity. TNF- α can either have protective or destructive effects, depending on the tissue/cell types from where it is secreted and the downstream signaling mechanisms by its receptors. Elevated or dysregulated expression and secretion of TNF- α could also contribute to pathological conditions. Chronic inflammatory disorders caused due to increased local production of TNF- α , include periodontal disease, inflammatory arthritis, and aseptic periprosthetic osteolysis, which involve bone loss in joints and teeth. Some oral diseases such as recurrent aphthous stomatitis, Behcet's disease, chronic periodontitis, and Sjogren Syndrome are also related to TNF- α imbalance. FDA-approved TNF blockers in the United States include Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol), and Simponi (golimumab). These blockers suppress the immune system via blocking the activity of TNF- α . FDA-approved and licensed anti-TNF- α medications for treating systemic diseases in the United States include Infliximab, Adalimumab, and etanercept. Here, we reviewed our current understanding of TNF- α and its blockers on immune- and inflammatory-mediated effects.

Keywords: TNF- α ; TNF- α Blockers; Oral Diseases; Periodontitis; Arthritis

Introduction

Cytokines are small proteins that almost every cell in the body produces. They are involved in the immune response. They also have a critical role in the inflammatory response. The proinflammatory cytokines activate the immune cells. They are also involved in the process of releasing other cytokines [1]. Estrogen suppresses TNF- α production [2], and several studies have shown the increased levels of inflammatory cytokines (TNF- α , Interleukin -1, -6, and Interferon-gamma) due to estrogen deficiency [3,4]. High levels of these inflammatory cytokines (e.g., TNF- α) contribute to bone loss by disrupting the balance between diminished osteoblastic bone formation and accelerated osteoclastic bone resorption activity in postmenopausal osteoporosis and other inflammatory diseases periodontitis, arthritis, etc. [5-7]. Carswell and his colleagues in 1975 introduced tumor necrosis factor-alpha (TNF- α). They named the tumor necrosis factor based on its necrosis effect on some tumors [8]. The first recognized TNF- α producing cells were macrophages [8], but later it was found that the secretion of this cytokine is not limited to macrophages. T-cells, B cells, neutrophils, and non-immune system cells such as fibroblast and endothelial cells can also be TNF- α producing cells [1,9]. Thus, TNF- α is a proven effective proinflammatory cytokine having diverse effects on various cell types.

TNF- α is also known in other names such as cachectin and endotoxin-induced factor [10]. It regulates infectious, inflammatory, and autoimmune events [11,12]. The significant part of TNF- α in several normal signaling pathways from proliferation to programmed cell death has been shown [13]. In the inflammation process, TNF- α induces the secretion of prostaglandin, which leads to vasodilation [14,15]. The role of TNF- α in the development of in vivo immune response was studied in TNF- α knockout mice. In the absence of TNF- α , mice demonstrated reduced contact hypersensitivity responses and a complete lack of B-cell follicles and humoral immune response [16]. We reviewed the following in this review: A) structure of TNF- α and its receptors, B and C) the potential association of TNF- α with bone loss, oral and other systemic diseases; D) Anti-TNF- α medications, E) Discussion, F) Conclusions

Structure of TNF-alpha and its Receptors

TNF- α belongs to the lymphotoxin (LT)/TNF family. Lymphotoxin (LT) is another superfamily member and has many similarities to TNF- α . Lymphotoxin (LT) was known as tumor necrosis factor-beta (TNF β) for many years. After several changes between these two names, it changed to lymphotoxin alpha (LT- α) [17]. TNF- α exists in two bioactive forms: transmembrane TNF (tm- TNF- α ~26kDa) and the soluble TNF (s- TNF- α ; ~17 kDa). The transmembrane TNF is also abbreviated as m-TNF- α [18-20]. The tm-TNF- α is a precursor of the s-TNF- α is expressed on the surface of several cell types, including activated macrophages and lymphocytes. The cleavage of tm-TNF- α produces the s- TNF- α form by a metalloprotease TNF- α converting enzyme (TACE). This proteolytic cleavage generates an N-terminal fragment of the TNF- α on the cell surface [21]. An increase in circulating s- TNF- α was related to the expression levels of TACE in atherosclerotic lesions of apolipoprotein E-deficient mice [22]. These fragments (s- and tm-TNF- α) initiate cellular signaling events via binding to type 1 or type 2 receptors on the cell surface; receptors are tumor necrosis factor receptor 1 (TNFR1; p55) and tumor necrosis factor receptor 2 (TNFR2; p75). Both tmTNF- α and s- TNF- α reacts with TNFR1 and TNFR2 (10), (Schematic diagram in Figure 1).

It was shown that s-TNF- α binds predominantly to TNFR1 and plays a vital role in the inflammatory immune response. In comparison, tm-TNF- α interacts primarily with TNFR2 and mediates cellular proliferation, survival, and other biological effects [23]. TNF- α has a role in the regulation of bone homeostasis and has been shown to have multiple effects on the differentiation of osteoblasts. It inhibits osteoblast differentiation via interfering bone morphogenic protein signaling [24,25]. It has also been shown that TNF- α induces Dickkopf-1 (DKK1) protein, affecting the differentiation of mesenchymal stem cells into osteoblasts and, hence, bone formation [24,25]. The pathogenesis of inflammatory bone diseases (e.g., periodontitis and rheumatoid arthritis) is associated with TNF- α levels and osteoclast bone resorption. Also, repression of osteoblast differentiation and bone formation is likely an additional mechanism when excess TNF- α is produced under inflammatory conditions [26,27].




Figure 1: Possible Biological effects of TNF- α mediated signaling pathways

Transmembrane TNF- α (tm-TNF- α) is a polypeptide with 233 amino acids (~26kDa) is cleaved between alanine and valine amino acid residues by an enzyme called TNF- α -converting enzyme (TACE). The resulting soluble sTNF- α with 157 amino acids (~17kDa) is released from the membrane. tm-TNF- α or sTNF- α are biologically active forms and mediate signaling via binding to TNFR1 (#1) or TNFR2 (#2).

Both TNFR1 and -2 mediate various physiological and pathological responses required for healthy and diseased conditions. The scheme shows the cellular signaling pathways play a vital role in proliferation, cytokine production, immunity, osteoblast differentiation, osteoclast resorption, and apoptosis via the activation of specific downstream signaling processes. The downstream signaling mechanism for a given activity is dependent on the cell type.

TNF- α therapy is provided dependent on the clinical situation. Five anti-TNF- α agents are indicated in the scheme (red). Among these five, infliximab, etanercept, and adalimumab have been clinically widely used. These agents bind to either s- or tm-TNF- α and block the effector cell signaling processes and the resultant effect of TNF- α (broken red arrow).

TmTNF- α can act as a bipolar molecule that conducts signals both as a ligand and a receptor in a cell-to-cell contact-dependent manner, i.e., tm-TNF- α can mediate the forward signaling cells via cell-to-cell communication (Scheme in Figure 1; TNFR-2 binding to tm-TNF- α of a neighboring cell). Tm-TNF- α can also transmit the reverse (outside-to-inside) signals back into the cells bearing tm-TNF- α , subsequently binding to its native receptor [28]. Reverse signaling triggered by tm-TNF- α and TNFR2 interaction played a significant role in maintaining tumor cell survival and metastasis [28]. s-TNF- α has been implicated in the steps of tumor development such as immune responses, tumorigenesis, proliferation, angiogenesis, and metastasis. BRAF is a human gene that encodes a protein called B-Raf.

Besides its role in tumor development, s-TNF- α also induces drug resistance to BRAF inhibitors [29,30]. Studies by Zhang et al. demonstrated that the expression of tm-TNF- α was correlated positively with the chemoresistance to anthracycline chemotherapy in breast cancer patients. Suppression of the reverse signaling by using a mutant form of tm-TNF- α with intact intracellular domain in a xenograft mouse model significantly enhanced the efficacy of doxorubicin [31]. Although s-TNF- α and tm-TNF- α are bioactive molecules, a detailed, comprehensive analysis is required to determine their bioactivities in terms of their binding specificity to TNFR1 and TNFR2 and signaling capacity. Identifying pathways will provide a novel therapeutic target for anti-TNF therapy related to s- or tm-TNF- α bioactivity.

The potential association of TNF- α with diseases associated with bone loss

Bacterial infection and its interaction with the host immune system led to periodontal diseases, including gingivitis and periodontitis. Consequently, the gingival epithelium also releases the proinflammatory cytokines besides the inflammatory mediators produced by the immune cells. Studies have linked periodontal diseases to cardiovascular diseases [32-34], rheumatoid arthritis [35,36], and cancers, including digestive, breast, prostate, and bladder cancers [36-40].

Periodontal disease: Periodontal disease is an inflammatory disease in acute or chronic form. Gingivitis is an inflammatory situation limited to gingivae. When the inflammation goes to the other supporting periodontal tissues, it is called periodontitis [41]. The prevalence of gingivitis is more than 80% of the population (children and adults). For periodontitis, the majority is related to age. It can be as low as 9% (for 18-24 years old) to more than 60% (for 65 years old) [42]. In chronic periodontitis, destruction of supporting tissues occur. It can be soft tissue like connective tissue or hard tissue like alveolar bone.

The initiation of this disease is related to specific anaerobic bacteria. But the host response to the bacteria is critical in the bone destruction of chronic periodontitis. The body's reaction to lipopolysaccharide (LPS), which is an endotoxin present in bacteria's outer membrane, causes the immune cells (T cells and macrophages) to be recruited to the area [43-45]. LPS/TLR pathways are activated either by mono- or polymicrobial infections, increasing the expression of proinflammatory molecules such as IL-6, IL-8, IL-1 β , and TNF- α by the immune cells. Elevating cytokine levels are one reason for periodontal tissue destruction in chronic periodontitis [42]. IL-1 and IL-6, and TNF- α have been implicated in osteoclastogenesis, osteoclast activity, alveolar bone loss. Progression of bone resorption can eventually lead to tooth loss [46]. TNF- α induces osteoclast formation and activity and reduces osteoblast differentiation and bone formation, shifting the balance towards more bone resorption without replacing the new bone formation [47]. LPS induced TNF- α production involves the ERK signaling pathway, and IL-10 synthesis requires JNK and/or p38 [48]. Periodontitis is not caused only by pathogens; the consequence of uncontrolled immune response and oxidative stress also impacts periodontal tissue damage. In vitro, in vivo, and human studies showed host modulation therapy seems a definite therapeutic approach to reach the clinical benefit level [49].

Most of the current treatment plans focus on treating bacterial infection, which is not practical for all patients. However, the host modulating treatment like anti-TNF- α can be a future direction for patients who poorly respond to the conventional treatment [50]. The only FDA-approved host modulating treatment for periodontitis is the sub-antimicrobial doxycycline. Reducing the inflammatory biomarkers and collagenase activity has been seen with sub-antimicrobial doxycycline treatment [51]. In different studies, the efficacy of the anti-TNF- α medications in decreasing periodontal tissue destruction has been shown. However, more clinical trials are essential to establish [50,52].

Chronic inflammation is also associated with carcinogenesis via the inflammatory mediators produced during periodontitis. The species of highly invasive anaerobic bacteria can transform the cells directly. Bacteria found in the sulcus or periodontal pocket could induce NF- κ B mediated actions, facilitate cell survival, initiate oncogenic pathways, reduce the expression of proapoptotic proteins, increase cell migration and invasion. An increase in the levels of EMT-related proteins could enhance the metastatic processes [53-55]. The actual mechanisms by which the bacteria-mediated carcinogenesis occurs and their tumorigenic effects need further elucidation.

Rheumatoid Arthritis (RA) and Ankylosing spondylitis (AS): RA is a systemic inflammatory disease that affects the joints, though the extra-articular involvements are common [56]. RA got more attention because of periodontal disease. Periodontal diseases and RA have several similar characteristics [36]. Periodontal diseases are more prevalent in RA patients. In patients with RA, oral health issues should be more thoroughly scrutinized [57]. Patients with advanced RA have a higher score for tooth loss [58]. In addition, they develop more significant temporomandibular joint (TMJ) and periodontal problems than patients who have periodontal disease and no RA [59]. TNF- α causes bone destruction, and the inhibition of TNF- α lags the bone loss processes in RA patients [60, 61]. Also, bone formation is substantially diminished at the erosion site of RA [62]. In a mouse model, *P. gingivalis* has been demonstrated to trigger arthritis and aggravated. *P. gingivalis* demonstrated a detrimental effect in inducing citrullination, systemic inflammation, and osteoclastogenesis, leading to bone damage [63,64].

The other chronic inflammatory is ankylosing spondylitis (AS), typified by sacroiliitis, spondylitis, and peripheral arthritis of large joints. TNF- α expression was found at the sac-

roiliitis site, and this cytokine's crucial role in AS pathology was identified via inhibition of TNF- α in AS patients. This inhibition reduced signs and symptoms of AS with a better physical function and quality of life in these AS patients [65,66]. Studies with *c-fos* $-/-$ heterozygous Tg197 TNF transgenic mice (*c-fos* $-/-$ hTNFtg) demonstrated that arthritic erosions could not develop in the absence of osteoclasts. Inhibition of osteoclast differentiation and activity changes damaging arthritis to a non-damaging one [67]. The association between AS and oral diseases like periodontitis has been shown in several studies [68-70]. The higher level of TNF- α is considered one of the reasons for arising AS and periodontitis [70,71]. The other oral disease related to AS is an oral ulcer that is significantly higher than the control group [70].

The potential association of TNF- α with other Oral and other systemic diseases

Recurrent aphthous stomatitis: Recurrent aphthous stomatitis (RAS) is defined as recurring ulcers in the oral cavity (several times during the year). RAS prevalence is high in developed countries, and most people experience RAS before 30 years [72]. Aphthous ulcers can be seen as a solitary disease or combined with other conditions like Behcet's disease, Crohn's disease, or aphthous related to HIV disease [73]. There is no specific laboratory test for diagnosis. So, other conditions should be ruled out before diagnosing RAS. The clinical and history evaluations can be helpful in the diagnosis process [74]. The peak for RAS onset is during adolescence (10-19 years old) [75]. The etiology of this disease is unknown. Several factors are related to RAS-like trauma, genetic predisposition, nutritional deficiencies, and stress. The process of RAS led to ulcer formation, and the aim of the treatment is to reepithelization and inflammation [76]. The imbalance of the immune system is also responsible for arising this disease. The cell-mediated immunity, e.g., T cells (TNF- α producers), is elevated in this disease [77]. TNF- α is also related to new lesions occurring [72]. Moreover, the salivary TNF- α level in RAS patients is higher (serum and saliva) in the active phase of the disease [77,78]. Controlling the TNF- α production is an effective treatment in RAS [78]. Balancing TNF- α decreases inflammation, and it can change the whole process from arising RAS [76]. At this time, there is no standard protocol for the duration of therapy with anti-TNF- α medications [72].

Behcet's disease: Behcet's disease (BD) is a chronic vasculitis involving multiple organs with unclear causing factors [79]. The monocytes of BD have shown higher secretion of some cytokines

like TNF- α [80]. There is a significant clinical difference between the involvement of males and females. However, women showed less mortality in comparison to men. Furthermore, females show fewer symptoms in organ involvement [79]. Oral manifestation of BD is usually the first symptom of this disease. They arise as recurrent aphthous ulcers with a recurrence of three times a year or more. The ulcers can be multiple or single. The lesions can be so painful that they prevent the patients from eating. Like RAS, based on the type of lesion (minor, major, herpetiform), they can be healed with or without a scar. These lesions can be seen on different oral cavity parts like gingival tissues, palate, and tongue [81]. High dosage immunosuppressive medications are administered in patients with vital organ injuries. It was adequate for the severe and refractory BD [82, 83]. The effects of the anti-TNF drug on BD have been evaluated. Although, the main administration for anti-TNF medications is recommended for patients with eye involvement [84]. The limitation of the studies for oral lesions is related to the low number of patients and limited time for the follow-up. [80,82]. The anti-TNF- α drugs for mucocutaneous ulcers in BD are effective when the other treatments fail [85].

Sjogren Syndrome: Sjogren syndrome (SS) is an autoimmune disease with lymphocytic infiltration to the exocrine glands [86]. The lymphocytic infiltration includes T-cells and B-cells. Overexpression of TNF- α in saliva and serum has been seen in SS [87]. Also, the intraglandular TNF- α is associated with acini destruction [88]. Lacrimal glands (eyes) and salivary glands (mouth) are the two main affected glands. So, dry eyes and dry mouth are common symptoms of this syndrome. This disease is more common in females and the middle ages [89]. In the absence and presence of other systemic diseases, it is called primary and secondary SS.

The systemic diseases accompanying SS are lupus erythematosus and rheumatoid arthritis [86]. Xerostomia (dry mouth) causes difficulty in eating and talking in SS patients. Another complication in the oral cavity is the higher prevalence of dental decay due to decreased saliva [90]. Initiating early treatment is essential to prevent the complication of SS. Treatment is mainly based on reducing the symptoms and decreasing the complications. The therapy focuses on increasing salivary secretion, preventing dental decay, periodontal disease, and oral infection [89]. Several anti-TNF medications like infliximab and etanercept are on the clinical trial for SS [91]. Based on the pathogenicity of SS, anti-TNF- α medications are a promising treatment for the future.

Anti-TNF- α medications

Currently available, the five TNF- α antagonists include etanercept, infliximab, adalimumab, golimumab, and certolizumab pegol. Table 1 provides the list of inhibitors, their binding specificity to TNF- α and/or LT- α , and possible therapy for different inflammatory diseases

1) Etanercept (Enbrel) is a soluble TNFR2 that can bind to TNF- α . Etanercept was the first approved medication for rheumatoid arthritis patients [92]. This antibody combines two extracellular parts of TNF receptor 2 (TNFR2) and Fc from human IgG1 [93]. Thus, etanercept can bind to both TNF- α and LT- α . But its binding to TNF- α is limited to the active form of TNF- α (trimer) [94].

2) Infliximab (Remicade), a chimeric monoclonal antibody, was first approved for human usage in Crohn's disease. Infliximab is a combined antibody from mice and humans. The medication constitutes about 75% of the human (constant region) and 25%

of murine (variable region) [11]. It is also used to treat Ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease [95,96]. Infliximab affects active (trimer) and inactive (monomer) forms of soluble TNF- α . It also can lyse the TNF- α expressing cells [94]. In BD, infliximab was used for controlling eye involvement. Administration of infliximab showed significant and rapid remission in BD patients with ocular inflammation who experienced other treatments' relapse [97]. However, infliximab usage is a fast and efficient treatment for acute ocular inflammation; this medication cannot treat irreversible retinal damage [98]. There are other considerations in BD patients who have mucocutaneous ulcers. These patients are more predisposed to infection and especially tuberculosis. Therefore, if anti-TNF- α medication is used, the patient should follow up to prevent other conditions [82]. There are limited studies in the usage of infliximab and etanercept for SS patients. Also, there are no studies related to the usage of adalimumab in SS patients. Therefore, more studies are needed to elucidate the effects of anti-TNF- α drugs in SS patients [88].

Table 1: List of TNF- α inhibitors and their characteristics

TNF- α inhibitors (Brand Name)	Etanercept (Enbrel)	Infliximab (Remicade)	Adalimumab (Humira)	Golimumab (Simponi)	Certolizumab pegol (Cimzia)
Structure	Humanized structure	Combined mice and human structure	Humanized structure	Humanized structure	Humanized structure
Binding Specificity	TNF- α and LT- α	TNF- α	TNF- α	TNF- α	TNF- α
Effect on TNF- α expressing cells	No lysis	Lysis	Lysis	No lysis	No lysis
Used to Treat diseases	Rheumatoid, Juvenile Idiopathic, and Psoriatic Arthritis	Crohn's Disease, Ulcerative colitis, Rheumatoid and Psoriatic Arthritis, Ankylosing Spondylitis, Moderate to Severe plaque Psoriasis, and Behçet's Disease	Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic arthritis	Rheumatoid and Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis	Crohn's disease, Rheumatoid arthritis, Ankylosing Spondylitis, Moderate to Severe plaque Psoriasis

3 and 4) adalimumab (Humira) and golimumab (Simponi) are fully human antibodies used as immunosuppressive medications [99, 100] for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis [101]. Adalimumab is an IgG1 monoclonal antibody with humanized structure. Adalimumab binds to TNF- α and prevents the interaction between TNF- α and its receptors. One of the advantages of adalimumab is subcutaneous administration [102]. Adalimumab has a higher affinity to TNF- α in comparison with infliximab and etanercept [72]. Body reaction against adalimumab is less because of this antibody's fully human and monoclonal structure [102]. However, adalimumab has a lysis effect on the cells with surface expression of TNF- α like infliximab [94]. Although the adverse effect profile of golimumab appears similar to other agents in the treatment of psoriatic arthritis, the longer-term safety profile of golimumab needs further elucidation [103].

5) Certolizumab pegol (aka Cimzia) is a Fab' fragment of a humanized anti-TNF- α antibody to treat inflammation and symptoms of Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Adalimumab, Golimumab, and Certolizumab pegol are used in adult patients who have obtained other medications that didn't work. Each compound can neutralize TNF- α ; evidence shows different efficacy in treating these diseases.

Although Food and drug administration (FDA) have approved several anti-TNF- α medications for human usage, the most commonly used TNF inhibitors are infliximab, adalimumab, and etanercept [104]. All these anti-TNF- α medications work through attachment to TNF- α (s- and tm-TNF- α) and prevent the activation of TNFRs [9]. Infliximab, adalimumab, and etanercept bind to and neutralize s-TNF- α but exert different effects on tm-TNF- α -expressing cells [105].

Discussion

TNF- α is a proinflammatory cytokine that exerts various effects (physiological and pathological) on different cell types. An increase in the production of TNF- α results in bone loss by osteoclast activation, which contributes to several common diseases, including osteoporosis, periodontitis, and rheumatoid arthritis; osteoclast activation by excess TNF- α affect bone structure under these conditions. Bisphosphonates are often used to treat osteoporosis. Bisphosphonates (BPs) inhibit osteoclast activity and hence bone resorption. Therefore, these

drugs are widely used for osteoporosis treatment. However, uncommon side effects including, atypical stress fractures and inflammatory eye disease, have been noticed. In addition, periodontitis is associated with BP-related osteonecrosis of the jaw [106]. The novel compound [4-(methylthio) phenylthio] methane bisphosphonate (MPMBP) was shown to have a therapeutic effect on inflammation-related bone loss in animal models [107-110]. However, the clinical impact of MPMBP needs further elucidation and more reports. We have previously demonstrated that anti-TNF- α and anti-TNFR1 blocks TNF- α mediated signaling involved in sealing ring formation and bone resorption by osteoclasts isolated from the bone marrow of long bones of mice [111,112]. However, our recent studies indeed have shown that TNF- α has the potential to reduce osteoblast differentiation and bone formation. TNF- α mediated effects on osteoblasts are inhibited by anti-TNF- α drugs, including etanercept and infliximab (unpublished observations). TNF- α gene silencing with topically applied siRNA nanoparticles has been developed as a calcium phosphate paste. The effect of this paste has been investigated in a rat periodontitis model in vivo [113]. Based on the available data, anti-TNF- α drugs have emerged as valuable therapeutic agents in treating many chronic inflammatory diseases. Therefore, the usage of anti-TNF- α drugs as a topical medication in the form of paste seems a promising approach in circumstances where excess TNF- α is produced (e.g., chronic periodontitis).

Conclusions

TNF- α elevation in the body is one of the underlying molecular mechanisms of several diseases. Host modulating treatments (like anti-TNF- α medications) are used for immune-mediated conditions. Several studies have shown that TNF- α therapy reduces osteoclast bone resorption. It has also been found to stimulate bone formation by osteoblasts in mice with rheumatoid arthritis via increasing Insulin-like 6 Peptide by polarized macrophages [114]. TNF- α inhibitors have been used for some conditions like rheumatoid arthritis for an extended period with successful results. The TNF- α imbalance was detected (systemically or locally) in some oral diseases, but there is limited information about anti-TNF- α medication and oral diseases. Using TNF- α inhibitors as a secondary line of treatment in severe oral conditions upon failure of other primary therapies can be life-changing. More clinical studies on the applicability of anti-TNF- α medications are needed for developing new treatment plans for oral diseases.

Acknowledgment

This research was funded by the National Institute of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases (5R01AR066044) to MAC and student support to Marjan Sharifi from the School of Dentistry, University of Maryland, Baltimore. However, the funders had no role in the study design, writing, or publishing of the review.

References

1. Kany S, Vollrath JT, Relja B (2019) Cytokines in Inflammatory Disease. *Int J molecular sci* 20.
2. Yang N, Wang G, Hu C, Shi Y, Liao L, Shi S, et al. (2013) Tumor necrosis factor α suppresses the mesenchymal stem cell osteogenesis promoter miR-21 in estrogen deficiency-induced osteoporosis. *J Bone Miner Res* 28: 559-73.
3. Weitzmann MN, Pacifici R (2006) Estrogen deficiency and bone loss: an inflammatory tale. *J Clin Invest* 116: 1186-94.
4. Clowes JA, Riggs BL, Khosla S (2005) The role of the immune system in the pathophysiology of osteoporosis. *Immunol Rev* 208: 207-27.
5. Khosla S, Riggs BL (2005) Pathophysiology of age-related bone loss and osteoporosis. *Endocrinol Metab Clin North Am* 34: 1015-30.
6. Raisz LG (2005) Pathogenesis of osteoporosis: concepts, conflicts, and prospects. *J Clin Invest* 115: 3318-25.
7. Chang J, Wang Z, Tang E, Fan Z, McCauley L, et al. (2009) Inhibition of osteoblastic bone formation by nuclear factor-kappaB. *Nat Med* 15: 682-9.
8. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, et al. (1975) An endotoxin-induced serum factor that causes necrosis of tumors. *Proc Natl Acad Sci U S A* 72: 3666-70.
9. Sedger LM, McDermott MF (2014) TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. *Cytokine Growth Factor Rev* 25: 453-72.
10. Chu WM (2013) Tumor necrosis factor. *Cancer Lett* 328: 222-5.
11. Tian T, Wang M, Ma D (2014) TNF- α , a good or bad factor in hematological diseases? *Stem Cell Investig* 1: 12.
12. Vassalli P (1992) The pathophysiology of tumor necrosis factors. *Annu Rev Immunol* 10: 411-52.
13. Holbrook J, Lara-Reyna S, Jarosz-Griffiths H, McDermott M (2019) Tumor necrosis factor signaling in health and disease. *F1000 Res* 8.
14. Johns DG, Webb RC (1998) TNF- α -induced endothelium-independent vasodilation: a role for phospholipase A2-dependent ceramide signaling. *Am J Physiol* 275: H1592-8.
15. Nakao S, Ogtata Y, Shimizu E, Yamazaki M, Furuyama S, et al. (2002) Tumor necrosis factor- α (TNF- α)-induced prostaglandin E2 release is mediated by the activation of cyclooxygenase-2 (COX-2) transcription via NFkappaB in human gingival fibroblasts. *Mol Cell Biochem* 238: 11-8.
16. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G (1996) Immune and inflammatory responses in TNF α -deficient mice: a critical requirement for TNF α in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. *The Journal of experimental medicine* 184: 1397-411.
17. Ruddle NH (2014) Lymphotoxin and TNF: how it all began a tribute to the travelers. *Cytokine Growth Factor Rev* 25: 83-9.
18. Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, et al. (2005) Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF- α . *Gastroenterology* 128: 376-392.
19. Grell M, Douni E, Wajant H, Lohden M, Clauss M, et al. (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. *Cell* 83: 793-802.
20. Aversa G, Punnonen J, de Vries JE (1993) The 26-kD transmembrane form of tumor necrosis factor- α on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation. *J Exp Med* 177: 1575-85.
21. Kriegler M, Perez C, DeFay K, Albert I, Lu SD (1988) A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. *Cell* 53: 45-53.
22. Canault M, Peiretti F, Kopp F, Bonardo B, Bonzi MF, et

- al. (2006) The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible contribution to elevated plasma levels of soluble TNF alpha receptors. *Atherosclerosis* 187: 82-91.
23. Grell M, Wajant H, Zimmermann G, Scheurich P (1998) The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. *Proc Natl Acad Sci U S A* 95: 570-5.
24. Mukai T, Otsuka F, Otani H, Yamashita M, Takasugi K, et al. (2007) TNF-alpha inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling. *Biochem Biophys Res Commun* 356: 1004-10.
25. Yamazaki M, Fukushima H, Shin M, Katagiri T, Doi T, et al. (2009) Tumor necrosis factor-alpha represses bone morphogenetic protein (BMP) signaling by interfering with the DNA binding of Smads through the activation of NF-kappaB. *J Biol Chem* 284: 35987-95.
26. Shiozawa S, Kuroki Y (1994) Osteoporosis in rheumatoid arthritis: a molecular biological aspect of connective tissue gene activation. *Tohoku J Exp Med* 173: 189-98.
27. Gilbert L, He X, Farmer P, Boden S, Kozlowski M, et al. (2000) Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. *Endocrinology* 141: 3956-64.
28. Qu Y, Zhao G, Li H (2017) Forward and Reverse Signaling Mediated by Transmembrane Tumor Necrosis Factor-Alpha and TNF Receptor 2: Potential Roles in an Immunosuppressive Tumor Microenvironment. *Front Immunol* 8: 1675.
29. Balkwill F (2009) Tumour necrosis factor and cancer. *Nat Rev Cancer* 9: 361-71.
30. Balkwill F (2006) TNF-alpha in promotion and progression of cancer. *Cancer Metastasis Rev* 25: 409-16.
31. Zhang Z, Lin G, Yan Y, Li X, Hu Y, et al. (2018) Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells. *Oncogene* 37: 3456-70.
32. Janket SJ, Baird AE, Chuang SK, Jones JA (2003) Meta-analysis of periodontal disease and risk of coronary heart disease and stroke. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 95: 559-69.
33. Peng CH, Yang YS, Chan KC, Kornelius E, Chiou JY, et al. (2017) Periodontal Treatment and the Risks of Cardiovascular Disease in Patients with Type 2 Diabetes: A Retrospective Cohort Study. *Intern Med* 56: 1015-21.
34. Southerland JH, Taylor GW, Moss K, Beck JD, Offenbacher S (2006) Commonality in chronic inflammatory diseases: periodontitis, diabetes, and coronary artery disease. *Periodontol* 2000 40: 130-43.
35. Koziel J, Mydel P, Potempa J (2014) The link between periodontal disease and rheumatoid arthritis: an updated review. *Curr Rheumatol Rep* 16: 408.
36. Detert J, Pischon N, Burmester GR, Buttgerit F (2010) The association between rheumatoid arthritis and periodontal disease. *Arthritis Res Ther* 12: 218.
37. Sfreddo CS, Maier J, De David SC, Susin C, Moreira CHC (2017) Periodontitis and breast cancer: A case-control study. *Community Dent Oral Epidemiol* 45: 545-51.
38. Xie WZ, Jin YH, Leng WD, Wang XH, Zeng XT (2018) Periodontal Disease and Risk of Bladder Cancer: A Meta-Analysis of 298476 Participants. *Front Physiol* 9: 979.
39. Corbella S, Veronesi P, Galimberti V, Weinstein R, Del Fabbro M, Francetti L (2018) Is periodontitis a risk indicator for cancer? A meta-analysis. *PLoS One* 13: e0195683.
40. Fitzpatrick SG, Katz J (2010) The association between periodontal disease and cancer: a review of the literature. *J Dent* 38: 83-95.
41. Petersen PE, Ogawa H (2012) The global burden of periodontal disease: towards integration with chronic disease prevention and control. *Periodontol* 2000 60: 15-39.
42. Algate K, Haynes DR, Bartold PM, Crotti TN, Cantley MD (2016) The effects of tumour necrosis factor-alpha on bone cells involved in periodontal alveolar bone loss; osteoclasts, osteoblasts and osteocytes. *J Periodontal Res* 51: 549-66.
43. AlQranei MS, Chellaiah MA (2020) Osteoclastogenesis in periodontal diseases: Possible mediators and mechanisms. *J*

Oral Biosci 62: 123-30.

44. AlQranei MS, Senbanjo LT, Aljohani H, Hamza T, Chellaiah MA (2021) Lipopolysaccharide- TLR-4 Axis regulates Osteoclastogenesis independent of RANKL/RANK signaling. *BMC Immunol* 22: 23.
45. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. *Nat Immunol* 11: 373-84.
46. Dosseva-Panova VT, Popova CL, Panov VE (2014) Subgingival microbial profile and production of proinflammatory cytokines in chronic periodontitis. *Folia Med (Plovdiv)* 56: 152-60.
47. Nanes MS (2003) Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. *Gene* 321: 1-15.
48. van der Bruggen T, Nijenhuis S, van Raaij E, Verhoef J, van Asbeck BS (1999) Lipopolysaccharide-induced tumor necrosis factor alpha production by human monocytes involves the raf-1/MEK1-MEK2/ERK1-ERK2 pathway. *Infect Immun* 67: 3824-9.
49. Sulijaya B, Takahashi N, Yamazaki K (2019) Host modulation therapy using anti-inflammatory and antioxidant agents in periodontitis: A review to a clinical translation. *Arch Oral Biol* 105: 72-80.
50. Balta MG, Papathanasiou E, Blix IJ, Van Dyke TE (2021) Host Modulation and Treatment of Periodontal Disease. *J Dent Res* 100: 798-809.
51. Elashiry M, Morandini AC, Cornelius Timothius CJ, Ghaly M, Cutler CW (2021) Selective Antimicrobial Therapies for Periodontitis: Win the "Battle and the War". *Int J Mol Sci* 22.
52. Hajishengallis G, Chavakis T, Lambris JD (2020) Current understanding of periodontal disease pathogenesis and targets for host-modulation therapy. *Periodontol* 2000 84: 14-34.
53. Hoare A, Soto C, Rojas-Celis V, Bravo D (2019) Chronic Inflammation as a Link between Periodontitis and Carcinogenesis. *Mediators Inflamm* 2019: 1029857.
54. Arjunan P, Meghil MM, Pi W, Xu J, Lang L, et al. (2018) Oral Pathobiont Activates Anti-Apoptotic Pathway, Promoting both Immune Suppression and Oncogenic Cell Proliferation. *Sci Rep* 8: 16607.
55. Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, et al. (2013) *Fusobacterium nucleatum* promotes colorectal carcinogenesis by modulating E-cadherin/ β -catenin signaling via its FadA adhesin. *Cell Host Microbe* 14: 195-206.
56. Conforti A, Di Cola I, Pavlych V, Ruscitti P, Berardicurti O, et al. (2021) Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. *Autoimmun Rev* 20: 102735.
57. Venkataraman A, Almas K (2015) Rheumatoid Arthritis and Periodontal Disease. An Update. *N Y State Dent J* 81: 30-6.
58. Kasser UR, Gleissner C, Dehne F, Michel A, Willershausen-Zonnchen B, et al. (1997) Risk for periodontal disease in patients with longstanding rheumatoid arthritis. *Arthritis Rheum* 40: 2248-51.
59. Garib BT, Qaradaxi SS (2011) Temporomandibular joint problems and periodontal condition in rheumatoid arthritis patients in relation to their rheumatologic status. *J Oral Maxillofac Surg* 69: 2971-8.
60. Weaver AL (2004) The impact of new biologicals in the treatment of rheumatoid arthritis. *Rheumatology (Oxford)* 43 Suppl 3: iii17-iii23.
61. Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, et al. (2007) A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. *Arthritis Res Ther* 9: R61.
62. Walsh NC, Reinwald S, Manning CA, Condon KW, Iwata K, Burr DB, et al. (2009) Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. *J Bone Miner Res* 24: 1572-85.
63. Perricone C, Ceccarelli F, Saccucci M, Di Carlo G, Bogdanos DP, et al. (2019) *Porphyromonas gingivalis* and rheumatoid arthritis. *Curr Opin Rheumatol* 31: 517-24.

64. Schmickler J, Rupprecht A, Patschan S, Patschan D, Müller GA, et al. (2017) Cross-Sectional Evaluation of Periodontal Status and Microbiologic and Rheumatoid Parameters in a Large Cohort of Patients With Rheumatoid Arthritis. *J Periodontol* 88: 368-79.
65. Braun J, Sieper J (2007) Ankylosing spondylitis. *Lancet* 369: 1379-90.
66. van der Heijde D, Salonen D, Weissman BN, Landewé R, Maksymowych WP, et al. (2009) Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. *Arthritis Res Ther* 11: R127.
67. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, et al. (2002) Osteoclasts are essential for TNF-alpha-mediated joint destruction. *J Clin Invest* 110: 1419-27.
68. Pandey A, Rajak R, Pandey M (2020) Periodontal diseases and its association with disease activity in ankylosing spondylitis/SpA: A systematic review. *Eur J Rheumatol*.
69. Karataş E, Kul A, Tepecik E (2020) Association of ankylosing spondylitis with radiographically and clinically diagnosed apical periodontitis: A cross-sectional study. *Dent Med Probl* 57: 171-5.
70. Abbood HM, Pathan E, Cherukara GP (2018) The link between ankylosing spondylitis and oral health conditions: two nested case-control studies using data of the UK Biobank. *J Appl Oral Sci* 27: e20180207.
71. Garcia-Montoya L, Emery P (2021) Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials. *Expert Opin Investig Drugs* 30: 1109-24.
72. Ranganath SP, Pai A (2016) Is Optimal Management of Recurrent Aphthous Stomatitis Possible? A Reality Check. *J Clin Diagn Res* 10: Ze08-ze13.
73. O'Neill ID (2012) Efficacy of tumor necrosis factor-alpha antagonists in aphthous ulceration: review of published individual patient data. *J Eur Acad Dermatol Venereol* 26: 231-35.
74. Ship JA (1996) Recurrent aphthous stomatitis. An update. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 81: 141-7.
75. Chavan M, Jain H, Diwan N, Khedkar S, Shete A, Durkar S (2012) Recurrent aphthous stomatitis: a review. *J Oral Pathol Med* 41: 577-83.
76. Suharyani I, Fouad Abdelwahab Mohammed A, Muchtaridi M, Wathoni N, Abdassah M (2021) Evolution of Drug Delivery Systems for Recurrent Aphthous Stomatitis. *Drug Des Devel Ther* 15: 4071-89.
77. Shen C, Ye W, Gong L, Lv K, Gao B, et al. (2021) Serum interleukin-6, interleukin-17A, and tumor necrosis factor-alpha in patients with recurrent aphthous stomatitis. *J Oral Pathol Med* 50: 418-23.
78. Chaudhuri K, Nair KK, Ashok L (2018) Salivary levels of TNF-alpha in patients with recurrent aphthous stomatitis: A cross-sectional study. *J Dent Res Dent Clin Dent Prospects* 12: 45-8.
79. Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, et al. (2003) The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. *Medicine (Baltimore)* 82: 60-76.
80. Hatemi G, Seyahi E, Fresko I, Talarico R, Uçar D, et al. (2021) One year in review 2021: Behçet's syndrome. *Clin Exp Rheumatol* 39 Suppl 132: 3-13.
81. Kokturk A (2012) Clinical and Pathological Manifestations with Differential Diagnosis in Behçet's Disease. *Pathology Res Int* 2012: 690390.
82. Sfikakis PP, Markomichelakis N, Alpsoy E, Asaad-Khalil S, Bodaghi B, et al. (2007) Anti-TNF therapy in the management of Behçet's disease--review and basis for recommendations. *Rheumatology (Oxford)* 46: 736-41.
83. Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, et al. (2015) Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. *J Autoimmun* 62: 67-74.
84. Hu Y, Huang Z, Yang S, Chen X, Su W, et al. (2020) Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha

Agents Treatment in Behçet's Disease-Associated Uveitis: A Systematic Review and Meta-Analysis. *Front Pharmacol* 11: 941.

85. Alpsoy E, Leccese P, Emmi G, Ohno S (2021) Treatment of Behçet's Disease: An Algorithmic Multidisciplinary Approach. *Front Med (Lausanne)* 8: 624795.

86. Nair JJ, Singh TP (2017) Sjogren's syndrome: Review of the aetiology, Pathophysiology & Potential therapeutic interventions. *J Clin Exp Dent* 9: e584-9.

87. Jung JY, Kim JW, Kim HA, Suh CH (2021) Salivary Biomarkers in Patients with Sjögren's Syndrome-A Systematic Review. *Int J Mol Sci* 22.

88. Meijer JM, Pijpe J, Bootsma H, Vissink A, Kallenberg CG (2007) The future of biologic agents in the treatment of Sjögren's syndrome. *Clin Rev Allergy Immunol* 32: 292-7.

89. Kassan SS, Moutsopoulos HM (2004) Clinical manifestations and early diagnosis of Sjogren syndrome. *Arch Intern Med* 164: 1275-1284.

90. Fox PC, Bowman SJ, Segal B, Vivino FB, Murukutla N, et al. (2008) Oral involvement in primary Sjogren syndrome. *J Am Dent Assoc* 139: 1592-1601.

91. Parisi D, Chivasso C, Perret J, Soyfoo MS, Delporte C (2020) Current State of Knowledge on Primary Sjögren's Syndrome, an Autoimmune Exocrinopathy. *J Clin Med* 9.

92. Haraoui B, Bykerk V (2007) Etanercept in the treatment of rheumatoid arthritis. *Ther Clin Risk Manag* 3: 99-105.

93. Marotte H, Cimaz R (2014) Etanercept - TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers? *Expert Opin Biol Ther* 14: 569-72.

94. Mpofo S, Fatima F, Moots RJ (2005) Anti-TNF-alpha therapies: they are all the same (aren't they?). *Rheumatology (Oxford)* 44: 271-3.

95. Melsheimer R, Geldhof A, Apaolaza I, Schaible T (2019) Remicade® (infliximab): 20 years of contributions to science and medicine. *Biologics* 13: 139-78.

96. Ohno S, Umebayashi I, Matsukawa M, Goto T, Yano T (2019) Safety and efficacy of infliximab in the treatment of re-

fractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan. *Arthritis Res Ther* 21: 2.

97. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamani P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behçet's disease. *Lancet* 358: 295-6.

98. Saleh Z, Arayssi T (2014) Update on the therapy of Behçet disease. *Therapeutic advances in chronic disease* 5: 112-34.

99. Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, et al. (2016) Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. *Health Technol Assess* 20: 1-610.

100. Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, et al. (2016) Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. *Health Technol Assess* 20: 1-326.

101. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, et al. (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis* 73: 492-509.

102. Plosker GL, Lyseng-Williamson KA (2007) Adalimumab: in Crohn's disease. *BioDrugs* 21: 125-32.

103. Yang H, Epstein D, Bojke L, Craig D, Light K, et al. (2011) Golimumab for the treatment of psoriatic arthritis. *Health Technol Assess* 15 Suppl 1: 87-95.

104. Lis K, Kuzawinska O, Balkowiec-Iskra E (2014) Tumor necrosis factor inhibitors - state of knowledge. *Arch Med Sci* 10: 1175-85.

105. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T (2010) Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. *Rheumatology (Ox-*

ford) 49: 1215-28.

106. Thumbigere-Math V, Michalowicz BS, Hodges JS, Tsai ML, Swenson KK, et al. (2014) Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw. *J Periodontol* 85: 226-33.

107. Takaoka Y, Nagai H, Mori H, Tanahashi M (1997) The effect of TRK-530 on experimental arthritis in mice. *Biol Pharm Bull* 20: 1147-50.

108. Tanahashi M, Koike J, Kawabe N, Nakadate-Matsushita T (1998) Inhibitory effect of TRK-530 on inflammatory cytokines in bone marrow of rats with adjuvant arthritis. *Pharmacology* 56: 237-41.

109. Tanahashi M, Funaba Y, Itoh M, Kawabe N, Nakadate-Matsushita T (1998) Inhibitory effects of TRK-530 on rat adjuvant arthritis. *Pharmacology* 56: 242-51.

110. Shinoda H, Takeyama S, Suzuki K, Murakami S, Yamada S (2008) Pharmacological topics of bone metabolism: a novel bisphosphonate for the treatment of periodontitis. *J Pharmacol Sci* 106: 555-8.

111. Ma T, Sadashivaiah K, Madayiputhiya N, Chellaiah MA (2010) Regulation of sealing ring formation by L-plastin and cortactin in osteoclasts. *J Biol Chem* 285 (2010) 29911-24

112. Chellaiah MA, Ma T, Majumdar S (2018) L-plastin phosphorylation regulates the early phase of sealing ring formation by an actin-bundling process in mouse osteoclasts. *Exp Cell Res* 372: 73-82

113. Tenkumo T, Rojas-Sánchez L, Vanegas Sáenz JR, Oga-
wa T, et al. (2020) Reduction of inflammation in a chronic periodontitis model in rats by TNF- α gene silencing with a topically applied siRNA-loaded calcium phosphate paste. *Acta Biomater* 105: 263-279.

114. Yi X, Liu X, Kenney HM, Duan R, Lin X, et al. (2021)

Submit your manuscript to a JScholar journal and benefit from:

- ☞ Convenient online submission
- ☞ Rigorous peer review
- ☞ Immediate publication on acceptance
- ☞ Open access: articles freely available online
- ☞ High visibility within the field
- ☞ Better discount for your subsequent articles

Submit your manuscript at
<http://www.jscholaronline.org/submit-manuscript.php>